Literature DB >> 18813950

Age-associated differences in prevalence of group A streptococcal type-specific M antibodies in children.

Preeti Jaggi1, James B Dale, Edna Chiang, Poonam Beniwal, William Kabat, Stanford T Shulman.   

Abstract

Our prior studies of the molecular epidemiology of group A streptococcus (GAS) pharyngitis indicated that the most common emm types associated with pediatric pharyngitis in North America were 12, 1, 28, and 4. We previously reported that the proportions of pediatric pharyngitis due to emm types 12 and 4 decreased with increasing age throughout childhood. We hypothesized that this is due to age-associated acquisition of antibodies to the amino-terminal type-specific region of common GAS M proteins during childhood. We sought to demonstrate this in sera from healthy children by using ELISAs for M 12, 1, 28, and 4. Enzyme-linked immunosorbent assays (ELISA) using chemically synthesized peptides copying amino-terminal type-specific regions of the M proteins were performed on sera from four age groups of healthy children (group I: 3-6 years, group II: 7-10 years, group III: 11-14 years, group IV: 15-18 years). ELISA data were correlated with opsonophagocytic assays for a subset of sera and M 1 GAS. Sera from healthy 12-20-month-old children were used as negative controls. Our results showed that the highest percentage of positivity was for M12, which also showed progressive seropositivity in older children. For the other serotypes, the highest seroprevalence rates were in the 11-14-year-old age group. The presence of ELISA antibodies against M1 correlated with opsonophagocytic activity, a previously studied indicator of immunologic protection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18813950     DOI: 10.1007/s00431-008-0819-6

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  12 in total

1.  The effect of penicillin prophylaxis on streptococcal disease rates and the carrier state.

Authors:  L W WANNAMAKER; F W DENNY; W D PERRY; C H RAMMELKAMP; G C ECKHARDT; H B HOUSER; E O HAHN
Journal:  N Engl J Med       Date:  1953-07-02       Impact factor: 91.245

2.  Group A streptococcal pharyngitis serotype surveillance in North America, 2000-2002.

Authors:  Stanford T Shulman; Robert R Tanz; William Kabat; Kathleen Kabat; Emily Cederlund; Devendra Patel; Zhongya Li; Varja Sakota; James B Dale; Bernard Beall
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079

3.  Age influences the emm type distribution of pediatric group A streptococcal pharyngeal isolates.

Authors:  Preeti Jaggi; Robert R Tanz; Bernard Beall; Stanford T Shulman
Journal:  Pediatr Infect Dis J       Date:  2005-12       Impact factor: 2.129

4.  Sequence and type-specific immunogenicity of the amino-terminal region of type 1 streptococcal M protein.

Authors:  W Kraus; E Haanes-Fritz; P P Cleary; J M Seyer; J B Dale; E H Beachey
Journal:  J Immunol       Date:  1987-11-01       Impact factor: 5.422

Review 5.  The global burden of group A streptococcal diseases.

Authors:  Jonathan R Carapetis; Andrew C Steer; E Kim Mulholland; Martin Weber
Journal:  Lancet Infect Dis       Date:  2005-11       Impact factor: 25.071

6.  Type-specific immunity and pharyngeal acquisition of group A Streptococcus.

Authors:  N Guirguis; D W Fraser; R R Facklam; A El Kholy; L W Wannamaker
Journal:  Am J Epidemiol       Date:  1982-12       Impact factor: 4.897

7.  Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.

Authors:  Shelly A McNeil; Scott A Halperin; Joanne M Langley; Bruce Smith; Andrew Warren; Geoffrey P Sharratt; Darlene M Baxendale; Mark A Reddish; Mary C Hu; Steven D Stroop; Janine Linden; Louis F Fries; Peter E Vink; James B Dale
Journal:  Clin Infect Dis       Date:  2005-09-12       Impact factor: 9.079

8.  Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial.

Authors:  Karen L Kotloff; Mary Corretti; Kathleen Palmer; James D Campbell; Mark A Reddish; Mary C Hu; Steven S Wasserman; James B Dale
Journal:  JAMA       Date:  2004-08-11       Impact factor: 56.272

9.  A controlled study of penicillin therapy of group A streptococcal acquisitions in Egyptian families.

Authors:  A El Kholy; D W Fraser; N Guirguis; L W Wannamaker; B D Plikaytis; R A Zimmerman
Journal:  J Infect Dis       Date:  1980-06       Impact factor: 5.226

10.  Persistence of type-specific antibodies in man following infection with group A streptococci.

Authors:  R C LANCEFIELD
Journal:  J Exp Med       Date:  1959-08-01       Impact factor: 14.307

View more
  2 in total

1.  Naturally Acquired Protection Against Upper Respiratory Symptoms Involving Group A Streptococcus in a Longitudinal Cohort Study.

Authors:  Joseph A Lewnard; Lilith K Whittles; Anne-Marie Rick; Judith M Martin
Journal:  Clin Infect Dis       Date:  2020-11-05       Impact factor: 9.079

2.  Seven-year surveillance of emm types of pediatric Group A streptococcal pharyngitis isolates in Western Greece.

Authors:  George A Syrogiannopoulos; Ioanna N Grivea; Adnan Al-Lahham; Maria Panagiotou; Alexandra G Tsantouli; Aspasia N Michoula Ralf René Reinert; Mark van der Linden
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.